Magnetic resonance spectroscopy of neurodegenerative illness

Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics

Volumn , Issue , 2005, Pages 301-326

  Jenkins, Bruce G ^a   Choi, Ji Kyung ^a   Beal, M Flint ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84927039465     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544873.022     Document Type: Chapter

References (122)

1. Andreassen, O. A., Jenkins, B. G., Dedeoglu, A. et al. (2001a). Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J. Neurochem., 77, 383-90.
2. Andreassen, O. A., Dedeoglu, A., Ferrante, R. J. et al. (2001b). Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis., 8, 479-91.
3. Argov, Z. (1998). Functional evaluation techniques in mitochondrial disorders. Eur. Neurol., 39, 65-71.
4. Argov, Z. & Bank, W. J. (1991). Phosphorus magnetic resonance spectroscopy (31P MRS) in neuromuscular disorders. Ann. Neurol., 30, 90-7.
5. Badar-Goffer, R. S., Bachelard, H. S. & Morris P. G. (1990). Cerebral metabolism of acetate and glucose studied by 13C-n.m.r. spectroscopy. A technique for investigating metabolic compartmentation in the brain. Biochem. J., 266, 133-9.
6. Barbiroli, B., Montagna, P., Martinelli, P. et al. (1993). Defective brain energy metabolism shown by in vivo 31P MR spectroscopy in 28 patients with mitochondrial cytopathies. J. Cereb. Blood Flow Metab., 13, 469-74.
7. Barbiroli, B., Frassineti, C., Martinelli, P. et al. (1997). Coenzyme Q10improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell.Mol. Biol., 43, 741-9.
8. Barbiroli, B., Iotti, S. & Lodi, R. (1998). Aspects of human bioenergetics as studied in vivo by magnetic resonance spectroscopy. Biochimie, 80, 847-53.
9. Bartha, R., Drost, D. J. & Williamson, P. C. (1999). Factors affecting the quantification of short echo in-vivo 1H MR spectra: prior knowledge, peak elimination, and filtering. NMR Biomed., 12, 205-16.
10. Baslow, M. H. (2002). Evidence supporting a role for N-acetyl-Laspartate as a molecular waterpumpinmyelinated neurons in the central nervous system. An analytical review. Neurochem. Int., 40, 295-300.
11. Baslow, M. H. (2003). Brain N-acetylaspartate as a molecular water pump and its role in the etiology ofCanavan disease: a mechanistic explanation. J.Mol. Neurosci., 21, 185-90.
12. Beal, M. F., Brouillet, E., Jenkins, B. G. et al. (1993). Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci., 13, 4181-92.
13. Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R. & Schulz, J. B. (1994). Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann. Neurol., 36, 882-8.
14. Bendahan, D., Desnuelle, C., Vanuxem, D. et al. (1992). 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology, 42, 1203-8.
15. Birken, D. L. & Oldendorf, W. H. (1989). N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci. Biobehav. Rev., 13, 23-31.
16. Blass, J. P., Sheu, R. K. & Cedarbaum, J. M. (1988). Energy metabolism in disorders of the nervous system. Rev. Neurol., 144, 543-63.
17. Bluml, S., Moreno, A., Hwang, J. H. & Ross, B. D. (2001). 1-(13)C glucose magnetic resonance spectroscopy of pediatric and adult brain disorders. NMR Biomed., 14, 19-32.
18. Bluml, S., Moreno-Torres, A., Shic, F., Nguy, C.H. & Ross, B.D. (2002). Tricarboxylic acid cycle of glia in the in vivohumanbrain. NMR Biomed., 15, 1-5.
19. Bottomley, P. (1987). Spatial localization in NMR spectroscopy in vivo. Ann. NY Acad. Sci., 508, 333-8.
20. Brand, A., Richter-Landsberg, C. & Leibfritz, D. (1993). Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev. Neurosci., 15, 289-98.
21. Bristol, L. A. & Rothstein, J. D. (1996). Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann. Neurol., 39, 676-9.
22. Brownell, A. L., Jenkins, B. G., Elmaleh, D. R., Deacon, T.W., Spealman, R. D. & Isacson, O. (1998). Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nat. Med., 4, 1308- 12.
23. Chance, B., Leigh, J. S., Smith, D. S., Nioka, S. & Clark, B. J. (1986). Phosphorus magnetic resonance spectroscopy studies of the role of mitochondria in the disease process. Ann. NYAcad. Sci., 488, 140-53.
24. Choe, B. Y., Park, J. W., Lee, K. S. et al. (1998). Neuronal laterality in Parkinson's disease with unilateral symptom by in vivo 1H magnetic resonance spectroscopy. Invest. Radiol., 33, 450-5.
25. Choi J.-K., Kuestermann, E., Andreassen, O. A., Beal, M. F. & Jenkins, B. G. (2003). Atale of two mice: impaired glial-neuronal cycling in mouse models of Huntington's disease and amyotrophic lateral sclerosis. In International Society ofMagneticResonance inMedicine, p. 437. Toronto, Canada.
26. Cruz, C. J., Aminoff, M. J., Meyerhoff, D. J., Graham, S. H. & Weiner, M.W. (1997). ProtonMRspectroscopic imaging of the striatum in Parkinson's disease. Magn. Reson. Imaging, 15, 619-24.
27. Dager, S. R., Strauss, W. L., Marro, K. I., Richards, T. L., Metzger, G. D. & Artru, A. A. (1995). Proton magnetic resonance spectroscopy investigation of hyperventilation in subjects with panicdisorderandcomparisonsubjects.Am. J.Psychiatry, 152, 666-72.
28. Davie, C. A., Hawkins, C. P., Barker, G. J. et al. (1994). Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain, 117, 49-58.
29. De Stefano, N., Matthews, P. M. & Arnold, D. L. (1995a). Reversible decreases in N-acetylaspartate after acute brain injury. Magn. Reson.Med., 34, 721-7.
30. De Stefano, N., Matthews, P. M., Ford, B., Genge, A., Karpati, G. & Arnold, D. L. (1995b). Short-term dichloroacetate treatment improves indices of cerebralmetabolismin patients with mitochondrial disorders. Neurology, 45, 1193-8.
31. De Stefano, N., Matthews, P. M., Narayanan, S., Francis, G. S., Antel, J. P. & Arnold, D. L. (1997). Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology, 49, 1138-41.
32. Dijkhuizen, R. M., van Lookeren Campagne, M., Niendorf, T. et al. (1996). Status of the neonatal rat brain after NMDA-induced excitotoxic injury as measured by MRI, MRS and metabolic imaging. NMR Biomed., 9, 84-92.
33. Dimlich, R. V. & Nielsen, M. M. (1992). Facilitating postischemic reduction of cerebral lactate in rats. Stroke, 23, 1145-52; discussion 1152-63.
34. Dunlop, D. S., McHale, D. M. & Lajtha, A. (1992). Decreased brain N-acetylaspartate in Huntington's disease. Brain Res., 580, 44-8.
35. Ellis, C. M., Lemmens, G., Williams, S. C. et al. (1997). Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopa-treated Parkinson's disease: a proton magnetic resonance spectroscopy study. Neurology, 49, 438-44.
36. Endres, M., Namura, S., Shimizu-Sasamata, M. et al. (1998). Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J. Cereb. Blood Flow Metab., 18, 238-47.
37. Fenstermacher, M. J. & Narayana, P. A. (1990). Serial proton magnetic resonance spectroscopy of ischemic brain injury in humans. Invest. Radiol., 25, 1034-9.
38. Ferrante, R. J., Andreassen, O. A., Jenkins, B. G. et al. (2000). Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci., 20, 4389-97.
39. Fisher, M. (1995). Potentially effective therapies for acute ischemic stroke. Eur. Neurol., 35, 3-7.
40. Frahm, J., Merboldt, K. D. & Hanicke, W. (1987). Localized proton spectroscopy using stimulated echoes. J.Magn. Reson., 72, 502-8.
41. Frahm, J., Bruhn, H., Gyngell, M. L., Merboldt, K. D., Hanicke, W. & Sauter, R. (1989). Localized proton NMR spectroscopy in different regions of thehumanbrain in vivo.Relaxation times and concentrations of cerebral metabolites. Magn.Reson.Med., 11, 47-63.
42. Gadian, D. G. & Radda, G. K. (1981). NMR studies of tissue metabolism. Annu. Rev. Biochem., 50, 69-83.
43. Granot, J. (1986). Selected volume spectroscopy using stimulated echoes (VEST). Application to spatially localized spectroscopy and imaging. J.Magn. Reson., 70.
44. Gruetter, R., Novotny, E. J., Boulware, S. D. et al. (1994). Localized 13C NMR spectroscopy in the human brain of amino acid labeling from D-[1-13C]glucose. J. Neurochem., 63, 1377- 85.
45. Hahn, E. (1950). Spin echoes. Phys. Rev., 80, 580-94.
46. Harada, M., Tanouchi, M., Arai, K., Nishitani, H., Miyoshi, H. & Hashimoto, T. (1996). Therapeutic efficacy of a case of pyruvate dehydrogenase complex deficiency monitored by localized proton magnetic resonance spectroscopy. Magn. Reson. Imaging, 14, 129-33.
47. Hassel, B., Sonnewald, U. & Fonnum, F. (1995). Glial-neuronal interactions as studied by cerebral metabolism of [2-13C]acetate and [1-13C]glucose: an ex vivo 13C NMR spectroscopic study. J. Neurochem., 64, 2773-82.
48. Henshaw, R., Jenkins, B. G., Schulz, J. B. et al. (1994). Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res., 647, 161-6.
49. Hetherington, H.P., Pan, J.W., Mason, G.F. et al. (1996). Quantitative 1H spectroscopic imaging of human brain at 4.1 T using image segmentation. Magn. Reson.Med., 36, 21-9.
50. Higuchi, T., Fernandez, E. J., Maudsley, A. A., Shimizu, H., Weiner, M. W. & Weinstein, P. R. (1996). Mapping of lactate and N-acetyl-L-aspartate predicts infarction during acute focal ischemia: in vivo 1H magnetic resonance spectroscopy in rats. Neurosurgery, 38, 121-9; discussion 129-30.
51. Hilal, S. K., Maudsley, A. A., Simon, H. E. et al. (1983). In vivo NMR imagingof tissuesodiumin the intact cat beforeandafter acute cerebral stroke. AJNR Am. J. Neuroradiol., 4, 245-9.
52. Hoang, T. Q., Bluml, S., Dubowitz, D. J. et al. (1998). Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology, 50, 1033- 40.
53. Holshouser, B. A., Komu, M., Moller, H. E. et al. (1995). Localized protonNMRspectroscopy in the striatumof patients with idiopathic Parkinson's disease: a multicenter pilot study. Magn. Reson.Med., 33, 589-94.
54. Hossmann, K. A. (1994). Glutamate-mediated injury in focal cerebral ischemia: the excitotoxin hypothesis revised. Brain Pathol., 4, 23-36.
55. Hwang, J. H., Graham, G.D., Behar, K. L., Alger, J. R., Prichard, J.W. & Rothman, D. L. (1996). Short echo time proton magnetic resonance spectroscopic imaging of macromolecule and metabolite signal intensities in the human brain. Magn. Reson. Med., 35, 633-9.
56. Isaacks, R. E., Bender, A. S., Kim, C. Y., Shi, Y. F. & Norenberg, M. D. (1999). Effect of ammonia and methionine sulfoximine on myo-inositol transport in cultured astrocytes. Neurochem. Res., 24, 51-9.
57. Jenkins, B., Brouillet, E., Chen, Y. et al. (1996). Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J. Cereb. Blood FlowMetab., 16, 450-61.
58. Jenkins B., Chen, Y. & Rosen, B. eds. (1997). Investigating the Neurochemistry and Etiology of Neurodegenrative Disorders using Magnetic Resonance Spectroscopy. NewYork, NY:Wiley-Liss.
59. Jenkins, B. G. & Kraft, E. (1999). Magnetic resonance spectroscopy in toxic encephalopathy and neurodegeneration. Curr. Opin. Neurol., 12, 753-60.
60. Jenkins, B. G., Koroshetz, W. J., Beal, M. F. & Rosen, B. R. (1993). Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology, 43, 2689-95.
61. Jenkins, B. G., Burns, L., Pakzaban, P. et al. (1994). Spectroscopic studies of neurochemical changes in a primate model of neurodegeneration and neural transplantation. In: Society of Magnetic Resonance, p 1423. San Francisco.
62. Jenkins, B. G., Rosas, H. D., Chen, Y. C. et al. (1998). 1H NMR spectroscopystudiesofHuntington's disease:correlationswith CAG repeat numbers. Neurology, 50, 1357-65.
63. Jenkins, B. G., Klivenyi, P., Kustermann, E. et al. (2000). Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J. Neurochem., 74, 2108-19.
64. Kalra, S., Cashman, N. R., Genge, A. & Arnold, D. L. (1998). Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport, 9, 1757-61.
65. Kalra, S., Arnold, D. L. & Cashman, N. R. (1999). Biological markers in the diagnosisandtreatmentof ALS. J.Neurol. Sci., 165Suppl. 1, S27-32.
66. Kalyanapuram, R., Seshan, V. & Bansal, N. (1998). Threedimensional triple-quantum-filtered 23Na imaging of the dog head in vivo. J.Magn. Reson. Imaging, 8, 1182-9.
67. Keller, J. N., Kindy, M.S., Holtsberg, F.W. et al. (1998). Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J. Neurosci., 18, 687-97.
68. Kirschner, P. B., Jenkins, B. G., Schulz, J. B. et al. (1996). NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals. Brain Res., 713, 178-85.
69. Klunk, W. E., Xu, C., Panchalingam, K., McClure, R. J. & Pettegrew, J. W. (1996). Quantitative 1H and. 31P MRS of PCA extracts of postmortem Alzheimer's disease brain. Neurobiol. Aging, 17, 349-57.
70. Kogure, T. & Kogure, K. (1997). Molecular and biochemical events within the brain subjected to cerebral ischemia (targets for therapeutical intervention). Clin. Neurosci., 4, 179-83.
71. Kopito, R. R. (2000). Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol., 10, 524-30.
72. Koroshetz, W. J., Jenkins, B. G., Rosen, B. R. & Beal, M. F. (1997). Energy metabolism defects inHuntington's diseaseandeffects of coenzyme Q10. Ann. Neurol., 41, 160-5.
73. Kuzniecky, R., Palmer, C., Hugg, J. et al. (2001). Magnetic resonance spectroscopic imaging in temporal lobe epilepsy: neuronal dysfunction or cell loss? Arch. Neurol., 58, 2048-53.
74. Lebon, V., Petersen, K. F., Cline, G. W. et al. (2002). Astroglial contribution to brain energy metabolism in humans revealed by 13C nuclear magnetic resonance spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. J. Neurosci., 22, 1523-31.
75. Lee, W. T., Shen, Y. Z. & Chang, C. (2000). Neuroprotective effect of lamotrigine and MK-801 on rat brain lesions induced by 3- nitropropionic acid: evaluation by magnetic resonance imaging and in vivo proton magnetic resonance spectroscopy.Neuroscience, 95, 89-95.
76. Lin, A. P., Shic, F., Enriquez, C. & Ross, B. D. (2003). Reduced glutamate neurotransmission in patients with Alzheimer's disease - an in vivo (13)C magnetic resonance spectroscopy study. Magma, 16, 29-42.
77. Lin, S. P., Song, S. K., Miller, J. P., Ackerman, J. J. & Neil, J. J. (2001). Direct, longitudinal comparison of (1)H and (23)Na MRI after transient focal cerebral ischemia. Stroke, 32, 925-32.
78. Lodi, R., Schapira, A. H., Manners, D. et al. (2000). Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol., 48, 72-6.
79. Magistretti, P. J. & Pellerin, L. (1997). Metabolic coupling during activation. A cellular view. Adv. Exp.Med. Biol., 413, 161-6.
80. Mason, G. F., Behar, K. L., Rothman, D. L. & Shulman, R. G. (1992). NMR determination of intracerebral glucose concentration and transport kinetics in rat brain. J. Cereb. Blood FlowMetab., 12, 448-55.
81. Mason, G. F., Pan, J. W., Ponder, S. L., Twieg, D. B., Pohost, G. M. & Hetherington, H. P. (1994). Detection of brain glutamate and glutamine in spectroscopic images at 4.1 T.Magn. Reson.Med., 32, 142-5.
82. Mason, G. F., Gruetter, R., Rothman, D. L., Behar, K. L., Shulman, R. G. & Novotny, E. J. (1995). Simultaneous determination of the rates of the TCA cycle, glucose utilization, alphaketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J. Cereb. Blood Flow Metab., 15, 12- 25.
83. Matthews, P. M., Ford, B., Dandurand, R. J. et al. (1993). Coenzyme Q10with multiple vitamins isgenerally ineffectivein treatment of mitochondrial disease. Neurology, 43, 884-90.
84. Matthews, R. T., Yang, L., Jenkins, B. G. et al. (1998). Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci., 18, 156-63.
85. Pavlakis, S. G., Kingsley, P. B., Kaplan, G. P., Stacpoole, P.W., O'Shea, M. & Lustbader, D. (1998). Magnetic resonance spectroscopy: useinmonitoringMELAStreatment. Arch.Neurol., 55, 849-52.
86. Penn, A. M., Roberts, T., Hodder, J., Allen, P. S., Zhu, G. & Martin, W. R. (1995). Generalizedmitochondrial dysfunction inParkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology, 45, 2097-9.
87. Petroff, O. A., Graham, G. D., Blamire, A. M. et al. (1992). Spectroscopic imaging of stroke in humans: histopathology correlates of spectral changes. Neurology, 42, 1349-54.
88. Petroff, O. A., Pleban, L. A. & Spencer, D. D. (1995). Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, andGABAcontent of the epileptic human brain. Magn. Reson. Imaging, 13, 1197-211.
89. Petroff, O. A., Errante, L. D., Rothman, D. L., Kim, J. H. & Spencer, D. D. (2002). Neuronal and glial metabolite content of the epileptogenichumanhippocampus. Ann.Neurol., 52, 635-42.
90. Pettegrew, J. W., Klunk, W. E., Panchalingam, K., McClure, R. J. & Stanley, J. A. (1997). Magnetic resonance spectroscopic changes in Alzheimer's disease. Ann. NY Acad. Sci., 826, 282- 306.
91. Pfeuffer, J., Tkac, I., Provencher, S.W. & Gruetter, R. (1999). Toward an in vivo neurochemical profile: quantification of 18 metabolites in short-echo-time (1)H NMR spectra of the rat brain. J.Magn. Reson., 141, 104-20.
92. Pioro, E. P., Majors, A. W., Mitsumoto, H., Nelson, D. R. & Ng, T. C. (1999). 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla. Neurology, 53, 71-9.
93. Podo F. (1999). Tumour phospholipid metabolism. NMR Biomed., 12, 413-39.
94. Prichard, J., Rothman, D., Novotny, E. et al. (1991). Lactate rise detectedby1HNMRinhumanvisualcortexduringphysiologic stimulation. Proc. Natl Acad. Sci., USA, 88, 5829-31.
95. Provencher, S.W. (1993). Estimation of metabolite concentrations fromlocalized in vivo protonNMRspectra. Magn. Reson.Med., 30, 672-9.
96. Radda, G. K. (1992). Control, bioenergetics, and adaptation in health and disease: noninvasive biochemistry from nuclear magnetic resonance. FASEB J., 6, 3032-8.
97. Ross, B.D., Hoang, T. Q., Bluml, S. et al. (1999). In vivo magnetic resonance spectroscopy of human fetal neural transplants. NMR Biomed., 12, 221-36.
98. Rothstein, J.D., Van Kammen, M., Levey, A. I., Martin, L. J. & Kuncl, R.W. (1995). Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol., 38, 73-84.
99. Rubio-Gozalbo, M. E., Heerschap, A., Trijbels, J. M., Meirleir, L. D., Thijssen, H.O. & Smeitink, J. A. (1999). ProtonMRspectroscopy in a child with pyruvate dehydrogenase complex deficiency. Magn. Reson. Imaging, 17, 939-44.
100. Saunders, D. E. (2000). MR spectroscopy in stroke. Br. Med. Bull., 56, 334-45.
101. Schulz, J.B. & Dichgans, J. (1999). Molecular pathogenesis ofmovement disorders: are protein aggregates a common link in neuronal degeneration? Curr. Opin. Neurol., 12, 433-9.
102. Schulz, J. B., Matthews, R. T., Jenkins, B. G., Brar, P. & Beal, M. F. (1995a). Improved therapeutic window for treatment of histotoxic hypoxia with a free radical spin trap. J. Cereb. Blood Flow Metab., 15, 948-52.
103. Schulz, J.B., Henshaw, D. R., Siwek, D. et al. (1995b). Involvement of free radicals in excitotoxicity in vivo. J. Neurochem., 64, 2239- 47.
104. Schurr, A., West, C. A. & Rigor, B. M. (1988). Lactate-supported synaptic function in the rat hippocampal slice preparation. Science, 240, 1326-8.
105. Serles, W., Li, L. M., Antel, S.B. et al. (2001). Timecourse of postoperative recovery ofN-acetyl-aspartate in temporal lobe epilepsy. Epilepsia., 42, 190-7.
106. Shonk, T. K., Moats, R. A., Gifford, P. et al. (1995). Probable Alzheimer disease: diagnosis with proton MR spectroscopy [see comments]. Radiology, 195, 65-72.
107. Sibson, N. R., Dhankhar, A., Mason, G. F., Behar, K. L., Rothman, D. L. & Shulman, R. G. (1997). In vivo 13CNMRmeasurements of cerebral glutamine synthesis as evidence for glutamateglutamine cycling. Proc. Natl Acad. Sci., USA, 94, 2699- 704.
108. Siesjo, B. K. (1992). Pathophysiology and treatment of focal cerebral ischemia. Part II: Mechanisms of damage and treatment. J. Neurosurg., 77, 337-54.
109. Signoretti, S., Marmarou, A., Fatouros, P. et al. (2002). Application of chemical shift imaging for measurement of NAA in head injured patients. Acta. Neurochir. Suppl., 81, 373-5.
110. Simmons, M., Frandoza, C. & Coyle, J. (1991). Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience, 45, 37-45.
111. Smith, J. K., Castillo, M. & Kwock, L. (2003). MR spectroscopy of brain tumors. Magn. Reson. Imaging Clin. N. Am., 11, 415-29, v-vi.
112. Sotak, C. H. & Alger, J. R. (1991). A pitfall associated with lactate detection using stimulated-echo proton spectroscopy. Magn. Reson.Med., 17, 533-8.
113. Storey, E., Hyman, B., Jenkins, B. et al. (1992). MPP+ produces excitotoxic lesions in rat striatum due to impairment of oxidative metabolism. J. Neurochem., 58, 1271-8.
114. Tanabe, J. L., Vermathen, M., Miller, R., Gelinas, D., Weiner, M.W. & Rooney, W. D. (1998). Reduced MTR in the corticospinal tract and normal T2 in amyotrophic lateral sclerosis. Magn. Reson. Imaging, 16, 1163-9.
115. Taylor, D. L., Davies, S. E., Obrenovitch, T. P. et al. (1995). Investigation into the role ofN-acetylaspartate in cerebral osmoregulation. J. Neurochem., 65, 275-81.
116. Terao, S., Sobue, G., Yasuda, T., Kachi, T., Takahashi, M. & Mitsuma, T. (1995). Magnetic resonance imaging of the corticospinal tracts in amyotrophic lateral sclerosis. J. Neurol. Sci., 133, 66-72.
117. Thulborn, K. R., Gindin, T. S., Davis, D. & Erb, P. (1999). Comprehensive MR imaging protocol for stroke management: tissue sodium concentration as a measure of tissue viability in nonhuman primate studies and in clinical studies. Radiology, 213, 156-66.
118. Thurston, J. H., Sherman, W. R., Hauhart, R. E. & Kloepper, R. F. (1989). Myo-inositol: a newly identified nonnitrogenous osmoregulatory molecule in mammalian brain. Pediatr. Res., 26, 482-5.
119. Tkac, I., Andersen, P., Adriany, G., Merkle, H., Ugurbil, K. & Gruetter, R. (2001). In vivo 1H NMR spectroscopy of the human brain at 7 T. Magn. Reson.Med., 46, 451-6.
120. Urenjak, J., Williams, S. R., Gadian, D. G. & Noble, M.(1992). Specific expression of N-acetylaspartate in neurons, oligodendrocytetype- 2 astrocyte progenitors, and immature oligodendrocytes in vitro. J. Neurochem., 59, 55-61.
121. Urenjak, J., Williams, S. R., Gadian, D. G. & Noble, M. (1993). Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J. Neurosci., 13, 981-9.
122. Van Zijl, P. C., Davis, D., Eleff, S. M., Moonen, C. T., Parker, R. J. & Strong, J. M. (1997). Determination of cerebral glucose transport and metabolic kinetics by dynamicMRspectroscopy.Am. J. Physiol., 273, E1216-27.